GCA Altium advises Cheplapharm on its TLB refinancing
GCA Altium acted as exclusive debt advisor to Cheplapharm Arzneimittel GmbH on its successful debut on the syndicated and rated TLB market.
Cheplapharm is a family-owned pharmaceutical company offering branded off-patent specialty products. The Group has a unique international footprint and a broad portfolio of over 70 products across more than 10 therapeutic areas. Cheplapharm focuses on acquiring original well-established off-patent niche and legacy branded pharmaceuticals from large pharmaceutical companies and creating value through its global footprint.
The new credit facilities ensure that the Group’s long-term financing is flexible and sustainably secured. In addition to the return of existing loans and promissory notes, there is a significant amount of additional liquidity available to finance future M&A projects.
Sebastian F. Braun, CEO of Cheplapharm commented: „Following the successful establishment of a global partner network, Cheplapharm is now able to continue its long-standing success story due to the new financing structure by further scaling the business model.“
Johannes Schmittat, Managing Director at GCA Altium added: „The new financing structure offers Cheplapharm a significant increase in flexibility at attractive conditions and offers the option of adjustable increases to support further growth.”